Does Alnylam Lift All Oligo Boats? The Dicerna IPO

Dicerna’s debut stood out even in a hot market for biotech IPOs, but it is hard to sort out how much investor enthusiasm was driven by its specific technologies, rub-off from the recent Alnylam/ Sanofi-Genzyme deal, and demands of insiders who wanted liquidity but not dilution.